临沧阴道口有小疙瘩临沧女友小便刺痛,临沧有效治疗阴虱,临沧怀孕好久试纸能测出来,临沧女生下体有异味什么原因,临沧怎么样医治念珠菌阴道炎,临沧看妇科病挂号,临沧严重盆腔炎怎么治疗

BEIJING, March 11(Xinhuanet)-- People with more fat around their waist, often known as “apple shape”, may not have a greater risk of heart attack than those with fatter bottoms and hips, according to a new study published in Lancet as quotted by media reports Friday.This study funded by the Medical Research Council and British Heart Foundation, reviewed 220,000 individual records from 17 countries and monitored the occurrence of heart attacks or strokes based on body mass index (BMI) versus waist-hip circumference. It found that people with "apple-shaped" obesity were at a higher risk of having heart risks compared to those with general obesity as assessed by their BMI.  This contradicts previous claims that "apple shaped" bodies were three times more likely to suffer heart attacks than those with more generally distributed fat.But experts warn obesity is still bad for the heart, no matter where the fat is, and they argue there is confusion about the best way to measure it. "Regardless of how you measure it, being obese is bad for your heart. This study suggests that measuring your waist is no better than calculating your BMI but it's not time to throw away the tape measure just yet, “Dr Mike Knapton, associate medical director at the British Heart Foundation said."We tend to underestimate our body shape and size, so measuring our waist or checking our BMI are both quick and easy ways we can check our health at home."Besides, he also listed some other heart risk factors that we need to think about too, such as blood pressure, cholesterol, diabetes and smoking.

BEIJING, Feb. 18 (Xinhua) -- Jia Qinglin, China's top political advisor, urged the municipality of Beijing to intensify efforts to promote the development of service and manufacturing industries.Jia, chairman of the National Committee of the Chinese People's Political Consultative Conference, made the remarks during his inspection tour in Beijing from Wednesday to Friday.During the tour, Jia visited factories, construction sites and communities to exchange views with officials and civilians. He also listened to a report from the Beijing municipal government.Beijing has taken the lead in optimizing its industrial structure as the output of its service industry accounts for 75 percent of the revenue from all sectors, according to official sources of the city.Jia encouraged Beijing to continue to promote its service sector by focusing on producer services and expanding the city's service businesses overseas.While visiting Beijing Benz Automotive Co., Ltd., Jia called for the strengthening of technological innovation in order to boost high-end equipment manufacturing.Beijing should turn itself into a center for national technological innovation to contribute to the country's economic development, Jia said.He also stressed the better protection of forest resources and the more efficient use of water to develop modern agriculture.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

SAN FRANCISCO, March 21 (Xinhua) -- Microsoft on Monday sued Barnes & Noble, claiming patent infringement by the largest book retailer in the United States.Microsoft said it filed legal actions on Monday in both the U.S. International Trade Commission and the U.S. District Court of the Western District of Washington against Barnes & Noble, as well as Foxconn and Inventec, two manufacturers of Barnes & Noble's devices.According to Microsoft, the actions focus on the patent infringement by Barnes & Noble's Nook e-reader and tablet, both of which run Google's Android operating system.The patents at issue cover a range of functionality embodied in Android devices that are essential to the user experience, including natural ways of interacting with devices by tabbing through various screens to find the information they need, surfing the Web more quickly and interacting with documents and e-books, Microsoft said in a press release."The Android platform infringes a number of Microsoft's patents, and companies manufacturing and shipping Android devices must respect our intellectual property rights," Horacio Gutierrez, Microsoft's corporate vice president and deputy general counsel, was quoted by the press release as saying.Writing in a separate company blog post, Gutierrez said that the latest actions bring to 25 the total number of Microsoft patents in litigation for infringement by Android smartphones, tablets and other devices.He noted that Microsoft has established a licensing program to address Android's ongoing infringement, and leading Android smartphone manufacturer HTC has taken a license under this program.Amazon.com also signed a patent license with Microsoft last year covering its Kindle e-reader, he added."Unfortunately, after more than a year of discussions, Barnes & Noble, Foxconn and Inventec have so far been unwilling to sign a license, and therefore, we have no other choice but to bring legal action to defend our innovations," Gutierrez said in the blog post.